Company Overview and News
US dollar erased losses from the week prior, appreciating 0.8% to 94.827 following escalating trade concerns after the Trump administration unveiled a list of Chinese goods worth US$200bil will be taxed 10%. However, by the end of the week, US President Trump cited that he would try to negotiate a fair trade deal with China.
KUALA LUMPUR, July 13 — Persistent buying interest in index-linked counters and small capitalisation stocks against a backdrop of positive market sentiment spurred Bursa Malaysia to close stronger for the fifth consecutive trading.
PBLOF 5225 FORTIS 7036 1295 Q0F BSMAF IHHHF 532843 1818
KUALA LUMPUR, July 13 — Bursa Malaysia was broadly higher across the board this morning, joining Wall Street’s bullish bandwagon, as yesterday’s buying momentum on the back of improved market sentiment continued to boost investors’ risk appetite.
TGLVY 3204 PBLOF 0026 7113 TPGVF 1295 BSMAF 1818
KUALA LUMPUR, July 12 — Bursa Malaysia extended gains for a fourth consecutive day with the benchmark index closing at a near three-week high today, bolstered by positive regional sentiment and strong gains in index-linked counters led by Maybank.
HLFBF 3204 PBLOF 5225 3867 5819 1082 1295 Q0F BSMAF IHHHF 1818
(July 12): Most Southeast Asian stock markets edged higher on Thursday, with the Philippines touching a near one-month high and Indonesia extending gains for a fourth session, as broader Asian peers recovered slightly from the previous session's steep losses.
UOVEF PBLOF MLYBY MLYNF AYAAY 1295 U11 GIGNY 1155 G13 UOVEY GIGNF ALI AYAAF
KUALA LUMPUR (July 12): The FBM KLCI reversed its earlier losses and climbed 0.44% at midday break, tracking regional markets, lifted by gains including at banking heavyweights Malayan Banking Bhd and Pulic Bank Bhd.
PBLOF MLYBY SPMXF MLYNF BATS 4162 1295 7153 5168 1155 KLKBY 3204 2445 SPMXY 4456 3301 3867 7205 0026 1899 5819 HRGHY
KUALA LUMPUR (July 12): The FBM KLCI remained presured at mid-morning today, tracking regional markets as market sentiment stayed tepid with the spectre of a U.S.-China trade war still hanging over global markets.
HLFBF 7073 PBLOF 7113 4065 BATS TPGVF 4162 1295 7153 2089 KLKBY 3867 6139 7668 HRGHY UPBMF 1082 5168 0131 TGLVY 5139 2445 5216 0026 0900 1899 5819
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
2018-07-06 - Asif
Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...
Silicon Investor Message Boards
This table lists all message boards related to MYX:1295 / PUBLIC BANK BERHAD on message board site Silicon Investor.